Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation
Corresponding Author
Takehiko Mori
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Novartis Pharma Program for Clinical Therapeutics of Hematologic Malignancy, Keio University School of Medicine, Tokyo, Japan
Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanSearch for more papers by this authorYoshinobu Aisa
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorTakayuki Shimizu
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorRie Yamazaki
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorAi Mihara
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorTomoharu Yajima
Division of Gastroenterology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorToshifumi Hibi
Division of Gastroenterology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorYasuo Ikeda
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorShinichiro Okamoto
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Takehiko Mori
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Novartis Pharma Program for Clinical Therapeutics of Hematologic Malignancy, Keio University School of Medicine, Tokyo, Japan
Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanSearch for more papers by this authorYoshinobu Aisa
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorTakayuki Shimizu
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorRie Yamazaki
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorAi Mihara
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorTomoharu Yajima
Division of Gastroenterology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorToshifumi Hibi
Division of Gastroenterology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorYasuo Ikeda
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorShinichiro Okamoto
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Search for more papers by this authorAbstract
Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients. Am. J. Hematol., 2007. © 2007 Wiley-Liss, Inc.
References
- 1 McDonald GB,Hinds MS,Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation. Ann Intern Med 1993; 118: 255–267.
- 2 Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281–291.
- 3 Valteau-Couanet D,Benhamou E,Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937–942.
- 4 Vassal G,Kosciently S,Challine D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Phamacol 1996; 37: 247–253.
- 5 Meresse V,Hartmann O,Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992; 10: 135–141.
- 6 Essel JH,Thompson JM,Harman GS, et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784–2788.
- 7 Arceci RJ,Sande J,Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute leukemia. Blood 2005; 106: 1183–1188.
- 8 Mannucci PM. Hemostatic drugs. New Engl J Med 1998; 339: 245.
- 9 Dunn CJ,Goa K. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999; 57: 1005–1032.
- 10 Porte RJ,Leebeek FWG. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62: 2193–2211.
- 11 Dalmau A,Sabate A,Acosta P, et al. Tranexamic acid reduces red cell transfusion better than ε-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91: 29–34.
- 12 Berntorp E,Follrud C,Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2000; 86: 714–715.
- 13 Dalmau A,Sabate A,Koo M,Rafecas A,Figueras J,Jaurrieta E. Prophylactic use of tranexamic acid and incidence of arterial thrombosis in liver transplantation. Anesth Analg 2001; 93: 516.
- 14 Woo KS,Tse LKK,Woo JLF,Vallance-Owen J. Massive pulmonary throboembolism after tranexamic acid fibrinolytic therapy. Br J Clin Pract 1989; 43: 465–466.
- 15 Taparia M,Cordingley FT,Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002; 68: 307–309.
- 16 Salat C,Holler E,Kolb HJ, et al. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Leuk Lymphoma 1999; 33: 25–32.
- 17 Salat C,Holler E,Kolb HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89: 2184–2188.
- 18 Smith LH,Dixon JD,Stringham JR, et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107: 132–134.
Citing Literature
